Lupin Limited has informed the Exchange regarding a press release dated February 16, 2026, titled "Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex in Canada".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has signed a License and Supply Agreement with Spektus to commercialize DeslaFlex, a novel antidepressant, in the Canadian market. This gives Lupin the rights to market and distribute this new depression treatment through its established Canadian operations. The move expands Lupin's footprint in the Canadian pharmaceutical market and adds a new product in the central nervous system (CNS) therapy area. This is part of Lupin's ongoing strategy to grow its international business through partnerships and in-licensing deals.
This agreement strengthens Lupin's product portfolio in Canada and opens a new revenue stream in the growing antidepressant segment, though the financial impact is not yet disclosed and may be modest in the near term.